Accessibility Menu
Finch Therapeutics Group logo

Finch Therapeutics Group(OTC) FNCHQ

Market Cap$16.38MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2021)-98%
5 Year-97%
1 Year-15%
1 Month+1%
$10.20
+0.99%
+0.10Today
Finch Therapeutics Group last closing stock price
MetricPriceDate
Last closeUSD 10.202026-08-20
Finch Therapeutics Group stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0.99%USD 10.102026-08-13
1 month+0.99%USD 10.102026-07-21
3 month+36.91%USD 7.452026-05-20
Year to date-24.37%USD 13.492025-12-31
1 year-15.21%USD 12.032025-08-20
3 year+55.82%USD 6.552023-08-21
5 year-97.35%USD 384.902021-08-20
Since inception-98.41%USD 639.602021-03-19

Finch Therapeutics Group Financials at a Glance

Market Cap

$16.38MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$2.85M

Net Income (TTM)

-$14.17M

EPS (TTM)

$0.00

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

0.58 (Low)

Price

$10.20

Volume

3

Open

$10.20

Previous Close

$10.20

Daily Range

$10.20 - $10.20

52-Week Range

$2.00 - $16.10

Estimated Earnings Date

Aug 21, 2026

FNCHQ News

FDA

Why Finch Therapeutics Stock Is Skyrocketing Today

Keith SpeightsApr 29, 2022

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Finch Therapeutics Group

Finch Therapeutics Group, Inc. is a biotechnology company focused on developing microbiome-based therapeutics. The company utilizes its Human-First Discovery platform to engineer microbiome compositions aimed at addressing various diseases.

Products and Services
  • Microbiome drugs targeting various health conditions
  • Human-First Discovery platform for microbiome engineering
  • Research and development in microbiome therapeutics
Growth Outlook
  • Market potential for microbiome therapies is expanding rapidly
  • Continued investment in R&D to enhance product pipeline
  • Strategic partnerships may drive future growth opportunities
Financial Highlights
  • Recent quarterly revenue reported at $0, indicating early-stage development
  • Cash and cash equivalents of $16.03 million as of June 30, 2024
  • Trailing twelve months (TTM) net income shows a loss of $48.34 million
Finch Therapeutics Group, Inc. operates in a promising sector with significant growth potential. The company's focus on microbiome-based therapies positions it well within the expanding biotechnology landscape. Despite recent financial challenges, including a reported net loss, the available cash reserves provide a buffer for ongoing research and development efforts. The strategic direction and innovative approach may attract interest from investors looking for opportunities in the biotechnology field.
AI Generated • Aug 13, 2026

Industry

Biotechnology

Sector

Health Care

Employees

1

CEO

Matthew P. Blischak

Website

www.finchtherapeutics.com

Headquarters

Boston, MA 02109, US

FNCHQ Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-86.83%

Return on Capital

-51.15%

Return on Assets

-27.89%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$16.38MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

1.61M

Volume

3

Avg. Volume

1.14K

Financials (TTM)

Gross Profit

-$183.00K

Operating Income

-$19.74M

EBITDA

-$19.51M

Operating Cash Flow

-$18.06M

Capital Expenditure

$14.00K

Free Cash Flow

-$18.04M

Cash & ST Invst.

$16.04M

Total Debt

$28.99M

Finch Therapeutics Group Performance Analysis

Finch Therapeutics Group annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20212021-12-31USD 18,532,000N/A
20222022-12-31USD 861,000-95.4%
20232023-12-31USD 107,000-87.6%
20242024-12-31USD 0N/A
Finch Therapeutics Group sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32023-09-30N/A
Q42023-12-31N/A
Q12024-03-31-100.0%
Q22024-06-30N/A
Finch Therapeutics Group annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20212021-12-31USD -36.72N/A
20222022-12-31USD -72.1296.4%
20232023-12-31USD -46.59-35.4%
20242024-12-31USD -8.64-81.5%
Finch Therapeutics Group sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32023-09-3065.1%
Q42023-12-31-25.2%
Q12024-03-31-27.5%
Q22024-06-30-24.9%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2024YOY CHG

Revenue

$0.00

N/A

Gross Profit

-$44.00K

+22.8%

Gross Margin

0.00%

N/A

Market Cap

$16.38MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$16.38M

N/A

Employees

1

N/A

Net Income

-$4.83M

+30.4%

EBITDA

-$6.07M

+32.8%

Quarterly Fundamentals

Name
Q2 2024YOY CHG

Total Cash

$16.04M

-52.9%

Total Debt

$28.99M

-6.6%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$26.90M

-54.2%

Short Term Debt

$4.19M

+26.4%

Return on Assets

-27.89%

N/A

Return on Invested Capital

-40.49%

N/A

Free Cash Flow

-$4.73M

+48.4%

Operating Cash Flow

-$4.73M

+48.4%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
KTTAPasithea Therapeutics Corp.
$0.50+6.43%
QNRXQuoin Pharmaceuticals, Ltd.
$5.57+11.62%
HOWLWerewolf Therapeutics, Inc.
$0.89+107.17%
IMAImageneBio Inc
$5.70+1.60%

Trending Stocks

Symbol / CompanyPricePrice Chg
IBITiShares Bitcoin Trust
$43.78+0.06%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$9.82+0.11%
BITOProShares Trust - ProShares Bitcoin ETF
$10.45+0.06%
MARAMara Holdings
$11.06-0.01%

Questions About FNCHQ

What is the current price of Finch Therapeutics Group?

Finch Therapeutics Group is trading at $10.20 per share.

What is the 52-week range for Finch Therapeutics Group?

Over the past 52 weeks, Finch Therapeutics Group has traded between $2.00 and $16.10.

How much debt does Finch Therapeutics Group have?

As of the most recent reporting period, Finch Therapeutics Group reported total debt of $27.79M.

How much cash does Finch Therapeutics Group have on hand?

Finch Therapeutics Group reported $10.26M in cash and cash equivalents in its most recent financial results.

What is Finch Therapeutics Group’s dividend yield?

Finch Therapeutics Group does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services